Neogenomics, Inc. · NASDAQ:NEO
Neogenomics — Q3 2026 Earnings Presentation
26 slides from Neogenomics's earnings presentation, Oct 28, 2026
Slide 1: Q3 2026 Financial Results
Q3 2026 Financial Results October 28, 2026 Nasdaq: NEO
Slide 2: Safe Harbor Statements
Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. (“we,” ”us,” “our,” “NeoGenomics” or the “Company”). Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation, and the conference call and webcast in connection
Slide 3: Mission and Vision
Mission We take cancer personally. We partner with physicians to deliver actionable insights that guide personalized treatment decisions and improve outcomes – through a comprehensive oncology portfolio, integrated customer solutions, and an unwavering commitment to excellence. Vision A world where
Slide 4: Highlights – Third Quarter 2026
Highlights – Third Quarter 2026 Momentum continues to build, positioning NEO for future success FINANCIAL PERFORMANCE 13% 29% 53% 1 Clinical Revenue Growth NGS Revenue Growth Adjusted EBITDA Growth Delivered total company Driven by NGS volume Supported by YoY Adj. GM revenue of $209 million growth o
Slide 5: Executive Leadership and BoD Succession Plan
Executive Leadership and BoD Succession Plan A multi-year and deliberate plan rooted in a consistent strategy CHANGES EFFECTIVE JANUARY 4, 2027 K E Y T AK E AW AY S Warren Stone Tony Zook Cements our executive leadership team CEO & Board Member Executive Chairman Current President and COO Current CE
Slide 6: Our Focus Areas Remain Consistent
Our Focus Areas Remain Consistent Multiple, overlapping drivers fuel our growth and disciplined margin expansion Deliver Durable Drive MRD Operational NGS Growth Uptake Excellence Growth is supported by new Our broad menu, community Make targeted investments to drive products in Heme and ST, mix cha
Slide 7: NGS is Our Durable Performance Catalyst
NGS is Our Durable Performance Catalyst +29% NGS Revenue +17% NGS Volume CONSISTENT NGS GROWTH Expect over 25% YoY revenue growth in 2026 Expect mid-teens YoY volume growth in 2026 NGS Revenue ~1/3 of Clinical Revenue NGS Volume ~10% of Clinical Volume in Q3 29% 17% YoY YoY growth growth Large NGS P
Slide 8: RaDaR ST: A Strategic Growth Engine in MRD
RaDaR ST: A Strategic Growth Engine in MRD Accessing large, nascent, and rapidly growing MRD market for cancer recurrence monitoring TO TAL AD D R E S S A B L E M AR K E T C O V E R AG E 1 IO Monitoring (new) 3 Current Indications Currently Future Accessing Access to Subset of Breast >20% >40% of MR
Slide 9: IO Monitoring: A Cornerstone of our Launch
IO Monitoring: A Cornerstone of our Launch MolDx reimbursement opens a large, underpenetrated opportunity THE OPPORTUNITY WHY WE WIN TO TAL AD D R E S S AB L E M AR K E T Pan-tumor use cases Our portfolio ~$3.9B Standard treatment across many solid tumors Integrated menu from diagnosis to therapy se
Slide 10: Investing into our Channel & Customer Experience
Investing into our Channel & Customer Experience Commercial teams focused on Oncology and Pathology C O M M E R C I AL T E AM S CUSTOM ER EXPERIENCE Two dedicated ecosystems to drive growth Reducing Friction for ordering providers Integrated solutions Oncology and pathology testing from one partner,
Slide 11: Lab of the Future – Modernizing our Infrastructure
Lab of the Future – Modernizing our Infrastructure Six integrated initiatives to drive gross margin expansion Digital Pathology Instrument Platform Upgrades Strategic Procurement Savings Whole-slide imaging and Next-generation sequencing Optimized sourcing and digital diagnostic workflows and analyz
Slide 12: Q3 Financial Highlights & Updated Full-Year Guidance
Q3 Financial Highlights & Updated Full-Year Guidance
Slide 13: Strong Revenue and Adjusted EBITDA Growth
Strong Revenue and Adjusted EBITDA Growth Exceeding our quarterly commitments Revenue ($M) Adj EBITDA ($M) $209M $19M $188M $12M 11% 53% YoY YoY growth growth Q3 2025 Q3 2026 Q3 2025 Q3 2026 Quarterly financial information is unaudited. Growth corresponds to prior year period. Adjusted EBITDA is a n
Slide 14: Clinical Revenue Performance Drivers
Clinical Revenue Performance Drivers Clinical Revenue Revenue per Test Volume (tests) $195M $530 367k 361k AUP Increased $172M $476 11% 2/3 Mix | 1/3 RCM 13% 11% 2% Clinical Volume* YoY growth YoY growth YoY growth +2% Q3 2025 Q3 2026 Q3 2025 Q3 2026 Q3 2025 Q3 2026 Quarterly financial information i
Slide 15: Adjusted Gross Margin Expanded Over 300 bps
Adjusted Gross Margin Expanded Over 300 bps Expect well over 150 bps of adjusted GM expansion for full year 2026 Adj Gross Margin FY Outlook 49% 47.5%+ High-Margin 45% 46% Mix Shift & RCM Drives AUP Efficiencies from >300 >150 Lab of the Future bps bps Initiatives Q3 2025 Q3 2026 FY 2025 FY 2026 Est
Slide 16: Operating Expenses, Margins, and Cash Position
Operating Expenses, Margins, and Cash Position OPERATING EXPENSE ADJ. EBITDA ADJ. EBITDA M ARGIN TOTAL CASH $105M $19M 8.9% $139M +4% YoY1 +53% YoY +240 bps YoY Period-end O P E R AT I N G L E V E R AG E D I S C I P L I N E D M AR G I N E X P AN S I O N & C AS H • OpEx up 4% YoY1 to $105M, investmen
Slide 17: Updating Full Year 2026 Guidance
Updating Full Year 2026 Guidance Guidance as of October 28, 2026 July 28, 2026 ($ Millions) YoY% Growth Assumptions Guide ($ Millions) YoY% Growth • Clinical revenue to grow low-teens % • NGS revenue to grow over 25% Revenue $802–806 ~11% $807–809 ~11% • PanTracer LBx revenue in MSD millions at midp
Slide 18: Growth Catalysts 2026+
Growth Catalysts 2026+ PROGRESS THROUGH Q3 | 4 GOALS ACHIEVED | RaDaR ST INDICATIONS REMAIN ON TRACK 1 RaDaR ST launch — HPV- Head & Neck, Breast subset Achieved 2 PanTracer LBx MolDx reimbursement Achieved 3 Two new reimbursed indications for RaDaR ST IO Monitoring 2 Subs. Pending 4 Above market NG
Slide 19: © 2026 NeoGenomics Laboratories, Inc. All rights reserved. All other trademarks are the property
© 2026 NeoGenomics Laboratories, Inc. All rights reserved. All other trademarks are the property of their respective owners. Rev. 10.28.2026
Slide 20: Appendix
GENOMICS Appendix
Slide 21: Balance Sheet
Balance Sheet September 30, 2026 (unaudited, in thousands)
Slide 22: Income Statement
Income Statement September 30, 2026 (unaudited, in thousands)
Slide 23: Statements of Cash Flows
Statements of Cash Flows September 30, 2026 (unaudited, in thousands)
Slide 24: Adjusted Gross Margin
Adjusted Gross Margin September 30, 2026 (unaudited, in thousands) _________________ (1) Cost of revenue adjustments for the three months ended September 30, 2026, include $4.6 million of amortization and $0.4 million of stock-based compensation. Cost of revenue adjustments for the nine months ended
Slide 25: Adjusted EBITDA
Adjusted EBITDA September 30, 2026 (unaudited, in thousands) _________________ (1) For the three and nine months ended September 30, 2026, leadership transition costs include executive severance and executive retention costs. For the three months ended September 30, 2025, leadership transition costs
Slide 26: Adjusted EBITDA 2026 Guidance
Adjusted EBITDA 2026 Guidance (unaudited, in thousands) GAAP net loss in 2026 will be impacted by certain charges, including: (i) amortization, (ii) stock-based compensation, and (iii) other one-time expenses. These charges have been included in GAAP net loss available to stockholders and GAAP net l